Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir/ritonavir
Despite the rapid development of efficient and safe vaccines against COVID-19, the need to
confine the pandemic and treat infected individuals on an outpatient basis has led to the …
confine the pandemic and treat infected individuals on an outpatient basis has led to the …
An insight overview on COVID-19 mRNA vaccines: advantageous, pharmacology, mechanism of action, and prospective considerations
The worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has urged scientists to present some novel vaccine platforms during this pandemic to …
has urged scientists to present some novel vaccine platforms during this pandemic to …
Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19)
Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …
Oral nirmatrelvir/ritonavir therapy for COVID-19: the dawn in the dark?
Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main
protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related …
protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related …
COVID-19 in 2022—The Beginning of the End or the End of the Beginning?
C Del Rio, PN Malani - Jama, 2022 - jamanetwork.com
Now in the third yearof the coronavirus pandemic, well after the Omicron variant surge, both
in the US and globally the number of daily cases had been declining to their …
in the US and globally the number of daily cases had been declining to their …
[HTML][HTML] Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection
A Heyer, T Günther, A Robitaille, M Lütgehetmann… - Cell Reports …, 2022 - cell.com
We here investigate the impact of antiviral treatments such as remdesivir on intra-host
genomic diversity and emergence of SARS-CoV2 variants in patients with a prolonged …
genomic diversity and emergence of SARS-CoV2 variants in patients with a prolonged …
Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials
Y Gao, M Liu, Z Li, J Xu, J Zhang, J Tian - Clinical Microbiology and …, 2023 - Elsevier
Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …
COVID-19 in the Fall of 2023—Forgotten but Not Gone
C Del Rio, PN Malani - JAMA, 2023 - jamanetwork.com
Since the end of the US Public Health Emergency on May 11, 2023, there has been a desire
from elected officials and the public to put COVID-19 in the rearview mirror. However, the …
from elected officials and the public to put COVID-19 in the rearview mirror. However, the …
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
M Zur, T Peselev, S Yanko, V Rotshild, I Matok - Antiviral Research, 2023 - Elsevier
Background Remdesivir, molnupiravir, and nirmatrelvir/ritonavir are three antiviral agents
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …
Antiviral fibrils of self-assembled peptides with tunable compositions
The lasting threat of viral pandemics necessitates the development of tailorable first-
response antivirals with specific but adaptive architectures for treatment of novel viral …
response antivirals with specific but adaptive architectures for treatment of novel viral …